EGFR L747_S752del

CI-VAR-00002403Explore in graph →NP_005219.2:p.Leu747_Ser752delNM_005228.5:c.2239_2256delClinVar 177647 CIViC 890 rs121913440

Curated evidence

Evidence by cancer (7 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–7 of 7 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Non-Small Cell Carcinoma7
EGFR L747_S752del	Afatinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID2154 A phase 3 study of 345 stage IIIB-IV lung adenocarcinoma patients, reported improved median progression free survival (13.6 months vs. 6.9 months, HR: 0.47, 95% CI: 0.34-0.65, P=0.001) in EGFR mutatio… (full text at CIViC) PMID 23816960 · Sequist et al., 2013 · Open in CIViC	civic
EGFR L747_S752del	Erlotinib	Predictive	C	Supports Sensitivity Response	—	submitted	EID3796 A study of five clinical trials reported that chemotherapy na�ve non-small cell lung cancer patients with EGFR sensitizing mutations (exon 19 deletion, L858R, L861Q, or G719X) treated with erlotinib o… (full text at CIViC) PMID 19671843 · Jackman et al., 2009 · Open in CIViC	civic

ClinVar

Clinical significance (1)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

clinvarCurated1 interpretation · review status and star rating as assigned by ClinVar.

Variation	Clinical significance	Review status	Stars	Conditions	Origin	Submitters	Last evaluated	Source
177647	Likely pathogenic; drug response	no assertion criteria provided	0	Tyrosine kinase inhibitor response; Lung adenocarcinoma	somatic	2	Oct 28, 2006	clinvar